1 August 2024, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that it will publish the latest Phase I clinical data based on the safety and efficacy of its self-developed highly selective small molecule FGFR4 inhibitor irpagratinib (ABSK011) in treating advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression on the 2024 European Society of Oncology (ESMO) Annual Meeting. Compared to the data released at the 2023 ESMO conference,this new update will include more cases in the target dose group and their clinical outcomes. This ESMO Congress will be held in Barcelona, Spain from September 13 to 17, 2024.

Abbisko will present the following information at the 2024 ESMO:

Title: Updated Safety and Efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a Phase 1 study

Presentation Number: 983P

Presenter: Xiao-Ping Chen (Wuhan, China)

Onsite Poster display date: Monday, 16 September 2024